In a patient taking empagliflozin (Jardiance) 25 mg who now has a persistently reduced eGFR below 20 mL/min/1.73 m² on two consecutive measurements, should the dose be lowered to 10 mg?

Do Not Lower the Dose—Continue Jardiance 25 mg

In a patient already taking empagliflozin (Jardiance) 25 mg who develops persistently reduced eGFR below 20 mL/min/1.73 m², you should continue the current 25 mg dose without dose reduction, unless the patient initiates dialysis or experiences intolerable side effects. There is no evidence supporting dose reduction in this scenario, and current guidelines explicitly recommend continuation at the established dose.

Guideline-Based Rationale

The KDIGO 2022 guidelines provide clear direction: once an SGLT2 inhibitor is initiated, it is reasonable to continue therapy even if eGFR falls below 20 mL/min/1.73 m², unless it is not tolerated or kidney replacement therapy is initiated 1. This recommendation (Practice Point 1.3.6) makes no mention of dose reduction—only continuation versus discontinuation.

The 2024 BMJ guideline reinforces this approach, stating that SGLT2 inhibitors may be continued even if GFR drops below 20 mL/min/1.73 m² for individuals already on therapy (until dialysis initiation) 2. Again, no dose adjustment is suggested.

FDA Label Guidance

The FDA label for Jardiance states: "There are insufficient data to support a dosing recommendation in patients with eGFR below 20 mL/min/1.73 m²" 3. This does not recommend lowering to 10 mg—it simply acknowledges lack of specific dosing data in this population. The label further notes that heart failure studies enrolled patients with eGFR equal to or above 20 mL/min/1.73 m² with no dose adjustment recommended 3.

Critically, the label specifies that the 10 mg versus 25 mg distinction relates to glycemic control efficacy, not safety at low eGFR. The glucose-lowering benefit of 25 mg decreases with worsening renal function 3, but the cardiovascular and renal protective benefits—which are the primary reasons to continue therapy at this stage—persist regardless of dose.

Clinical Trial Evidence Supporting Continuation

The EMPEROR-Reduced and EMPEROR-Preserved trials both enrolled patients down to eGFR 20 mL/min/1.73 m² and demonstrated consistent cardiovascular and renal benefits across the entire spectrum of kidney function 4, 5. In EMPEROR-Reduced, empagliflozin reduced the composite kidney outcome by 53% in patients with CKD (HR 0.53; 95% CI 0.31-0.91) 4. The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73 m² and showed a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64-0.82) 6.

None of these trials used dose reduction strategies based on declining eGFR—patients remained on their assigned dose throughout the study period.

Why Dose Reduction Is Not Indicated

1. No safety signal: The trials and FDA label show empagliflozin is well-tolerated at eGFR <20 mL/min/1.73 m², with no increased adverse events requiring dose reduction 4, 5.

2. Mechanism of benefit: At this stage of CKD, the primary benefit is cardiorenal protection, not glycemic control. The hemodynamic effects (reduced intraglomerular pressure, decreased sympathetic activity, sodium modulation) that provide kidney and heart protection are dose-dependent and would be compromised by dose reduction 7.

3. Pharmacokinetics: While systemic exposure increases modestly with severe renal impairment (66% increase in AUC), this was not associated with increased adverse events and no dose adjustment was recommended based on pharmacokinetic studies 8.

Practical Management Algorithm

Continue Jardiance 25 mg if:

• Patient is tolerating the medication (no symptomatic hypotension, volume depletion, recurrent UTIs, or ketoacidosis)
• Patient is not yet on dialysis
• The medication was providing benefit (reduced HF hospitalizations, stable kidney function trajectory)

Discontinue (not reduce) Jardiance if:

• Dialysis is initiated 1, 3
• Intolerable side effects develop (severe volume depletion, recurrent genital infections, ketoacidosis)
• Patient experiences prolonged fasting, major surgery, or critical illness (temporary hold) 1

Monitor closely for:

• Volume status (especially if on concurrent diuretics—consider reducing diuretic dose, not SGLT2i dose) 1
• Acute kidney injury during intercurrent illness
• Ketoacidosis symptoms (even with normal glucose levels)
• Urinary tract and genital infections

Common Pitfall to Avoid

The most common error is assuming that lower eGFR requires lower SGLT2i dose. This misconception likely stems from other medications that require renal dose adjustment. However, SGLT2 inhibitors are unique: their primary benefit at advanced CKD stages is not glucose lowering but cardiorenal protection, which is maintained even when urinary glucose excretion (the glycemic mechanism) becomes minimal. Reducing the dose would potentially sacrifice protective benefits without clear safety justification.

The only scenario where you would stop (not reduce) empagliflozin is dialysis initiation, as the drug is contraindicated in dialysis patients 1, 3.